Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 14, 2016 1:08 PM ET


Company Overview of Cardigant Medical, Inc.

Company Overview

Cardigant Medical, Inc., a development stage biotechnology company, focuses on the development of novel biologic compounds and methods for local delivery for the treatment of acute coronary syndromes, carotid stenosis, and aortic valve stenosis. It plans to treat atherosclerosis and plaque stabilization using systemic and local delivery of large molecule therapeutics based on high density lipoprotein targets. The company’s lead drug product is based on the AApoA-1 protein, which has a specific role in the metabolism of lipids. Cardigant Medical, Inc. was founded in 2009 and is headquartered in Manhattan Beach, California. As of October 20, 2014, Cardigant Medical, Inc. was acquired by Takung...

1500 Rosecrans Avenue

Suite 500

Manhattan Beach, CA 90266

United States

Founded in 2009

1 Employees



Key Executives for Cardigant Medical, Inc.

Cardigant Medical, Inc. does not have any Key Executives recorded.

Cardigant Medical, Inc. Key Developments

Cardigant Medical Inc. Announces Management Changes

On October 20, 2014, Mr. Jerett Creed, Mr. Lei Wang and Mr. Yong Li resigned from all officers and directors positions they held with the company due to personal reasons and Mr. Xiao Di was appointed as the Chief Executive Officer, Chief Financial Officer and the sole director of the company.

Cardigant Medical Inc. Amends Article of Certificate of Incorporation

Effective September 19, 2014, Cardigant Medical Inc. amended article 4 of its Certificate of Incorporation to increase the total number of shares of common stock, par value $0.001 per share, it is authorized to issue from 50,000,000 to 1,000,000,000.

Cardigant Medical Inc. Announces Executive Changes, Effective September 22, 2014

On September 22, 2014, effective as William Pinon and Scott Merz, PhD resigned from the Board of Directors of Cardigant Medical Inc. At the time of his resignation, Mr. Pinon was Chairman of the Board. Dr. Merz did not hold any positions other than director.

Similar Private Companies By Industry

Company Name Region
Mountain View Pharmaceuticals, Inc. United States
Carolus Therapeutics, Inc. United States
Evolugate LLC United States
Xetrios Therapeutics, Inc. United States
General Genomics, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Cardigant Medical, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at